Alkaline Phosphatase in Metastatic Castration-Resistant Prostate Cancer: Reassessment of an Older Biomarker | Zendy

Daniel Heinrich | Zendy; Øyvind S. Bruland | Zendy; Theresa A. Guise | Zendy; Hiroyoshi Suzuki | Zendy; Oliver Sartor | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alkaline Phosphatase in Metastatic Castration-Resistant Prostate Cancer: Reassessment of an Older Biomarker

Author(s) -

Daniel Heinrich,

Øyvind S. Bruland,

Theresa A. Guise,

Hiroyoshi Suzuki,

Oliver Sartor

Publication year - 2018

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2018-0087

Subject(s) - cabazitaxel , prostate cancer , medicine , enzalutamide , docetaxel , radium 223 , oncology , context (archaeology) , abiraterone acetate , overall survival , biomarker , prostate specific antigen , disease , cancer , androgen deprivation therapy , bone metastasis , androgen receptor , paleontology , biochemistry , chemistry , biology

Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research